Seneffe, Belgium, July 19, 2018. Eckert & Ziegler BEBIG is now supplying seeds for the treatment of ophthalmic tumors and prostate cancer to Mexico. The ophthalmic IsoSeed® I25.S16 in COMS Plaques is even posing a premiere among Mexican ophthalmologists.
Left: IsoSeed® in COMS Plaques with loose seeds for ophthalmic brachytherapy
Right: IsoStrand® Cutting Fixture for manual seed strand cutting under radiation protection
The first ocular brachytherapy implant was performed in Mexico on June 2, 2018 at Hospital Español with IsoSeed® I25.S16, as part of the inaugurated ocular brachytherapy program. Dr. José Emiliano Fulda Graue, Specialist in Retina and Oncology, leader of the project in Mexico, with extensive experience in ocular brachytherapy says: "We are very pleased to finally offer ophthalmic brachytherapy to Mexican patients with uveal melanomas and retinoblastomas, as the treatment preserves the eye." The vice-president of the Pan American Society of Ocular Oncology explains: "With this form of radiotherapy, a radioactive plaque containing iodine-125 is sutured to the wall of the eye and left in place until the required dose of radiation has been delivered. A number of studies prove the good results of ophthalmic brachytherapy."
Meanwhile, Eckert & Ziegler BEBIG was also able to enter the Mexican market for prostate seed brachytherapy, with the Centro Médico ABC in Mexico City being the first hospital to perform an implantation with IsoStrand® seed chains. Just a few weeks later, Hospital Satélite, one of the pioneers in prostate seed brachytherapy in Mexico with more than 200 patients treated and excellent results, began treating its patients with the Eckert & Ziegler BEBIG stranded seeds. In Mexico City, clinics expect 50 to 60 patients a year.
About Eckert & Ziegler BEBIG
My partner in brachytherapy and radiation therapy
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the healthcare industry. Its core business is the production and distribution of medical products for the treatment of cancer, using brachytherapy. The company's headquarters are in Belgium, with production facilities in Germany and the USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company's products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists.
Eckert & Ziegler BEBIG employs approximately 145 people. The company has been listed on the Euronext stock exchange since April 1997.
Contact:
Annica Witt
Marketing Communication Manager
marketing@bebig.com
www.bebig.com